Clinical trials: Neoadjuvant Therapies
Breast Cancer, Estrogen Receptor Positive Tumor
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in…
- Conditions
- Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
- Trial name
- TOUCH (NCT03644186)
- Testing
- Paclitaxel, Trastuzumab, Pertuzumab
- Where
- 54 sites in Belgium, France and 2 more
- Volunteers
- 147 people
- Sponsor
- ETOP IBCSG Partners Foundation
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
Urothelial Carcinoma, Bladder Cancer
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).
- Trial name
- NCT01042795
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Bladder Cancer
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
This phase II trial studies how well fluorine F 18 Ara-G positron emission tomography (PET)/magnetic resonance (MR) imaging works in measuring clinical response to atezolizumab or patients with cancer receiving standard of care…
- Trial name
- NCT03007719
- Testing
- Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Lawrence Fong
Pancreas Cancer, Adenocarcinoma of the Pancreas
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
The purpose of this study is to determine the feasibility and safety of combining digoxin as a modulator of the hypoxia pathway in combination with FOLinic acid, 5-Fluorouracil, IRINotecan and OXaliplatin (FOLFIRINOX) in…
- Trial name
- NCT04141995
- Testing
- Digoxin, 5Fluorouracil, Calcium Leucovorin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
This phase II trial studies the effect of avelumab, gemcitabine and carboplatin before surgery compared with surgery alone in treating patients with muscle invasive bladder or upper urinary tract cancer who are not able to…
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
- Trial name
- NCT04871529
- Testing
- Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Small-Cell Lung Cancer
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage…
- Trial name
- IMforte (NCT05091567)
- Testing
- Atezolizumab, Lurbinectedin, Carboplatin
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
Muscle Invasive Bladder Cancer
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
- Trial name
- NIAGARA (NCT03732677)
- Testing
- Durvalumab, Cisplatin, Gemcitabine
- Where
- 188 sites in United States, Australia and 20 more
- Volunteers
- 1,063 people
- Sponsor
- AstraZeneca
Rectal Cancer
A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer
This study will assess the efficacy and safety of two different neoadjuvant treatment approaches including bevacizumab in newly diagnosed participants with high risk locally advanced rectal cancer.
- Trial name
- INOVA (NCT00865189)
- Testing
- Bevacizumab, Oxaliplatin, Folinic Acid
- Where
- 40 sites in France
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.
- Trial name
- NCT00556374
- Testing
- Denosumab, Non-steroidal aromatase inhibitor therapy, Zoledronic Acid
- Where
- 46 sites in Austria, Sweden
- Volunteers
- 3,420 people
- Sponsor
- Amgen
Myeloma Multiple
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
- Trial name
- NCT04816526
- Testing
- Descartes 08
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Cartesian Therapeutics
Breast Cancer
Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
We proposed to use 4 cycles of AC q 2 weeks, as used in the dose dense adjuvant study with GM-CSF support on days 3-9 of the cycle.
- Trial name
- NCT00256243
- Testing
- Doxorubicin, Cyclophosphamide, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Rita Sanghvi, Mehta
Squamous Cell Lung Cancer
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001
This will be a single-arm study to primarily evaluate the feasibility of administering necitumumab added to gemcitabine and cisplatin as neoadjuvant treatment in treatment-naïve patients with stage IB (tumor size >4cm), II or…
- Trial name
- NCT03574818
- Testing
- Necitumumab-Gemcitabine-Cisplatin, Evaluation to determine if patient is a candidate to proceeed with surgical resection or not
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery.
- Conditions
- Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
- Trial name
- NCT00861705
- Testing
- Bevacizumab, Carboplatin, Cyclophosphamide
- Where
- 448 sites in United States
- Volunteers
- 454 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
CHFR Methylation Status Esophageal Cancer Study
This is a Phase 2 Study of Paclitaxel with Cisplatin versus Fluoropyrimidine with a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies.
- Trial name
- J10130 (NCT01372202)
- Testing
- Paclitaxel, Cisplatin, Oxaliplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
The purpose of this trial is to study the activity of vemurafenib in untreated melanoma brain metastases harboring B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations that are not amenable to stereotactic radiosurgery…
- Trial name
- NCT01781026
- Testing
- Vemurafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Yale University
Lung Cancer, Small Cell
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
This is a Phase II, randomized, open-label, multi-center study in advanced (Stage IVA and IVB subjects per the International Association for the Study of Lung Cancer (IASLC) 2009 Lung cancer staging schema) non-squamous NSCLC…
- Trial name
- NCT01313663
- Testing
- pazopanib, pemetrexed
- Where
- 25 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed.
- Trial name
- NCT00104728
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non Small Cell Lung Cancer
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating…
- Trial name
- CheckMate 816 (NCT02998528)
- Testing
- Nivolumab, Cisplatin, Vinorelbine
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 505 people
- Sponsor
- Bristol-Myers Squibb